ICML 2023 | REDIRECT results: AFM13 in patients with CD30+ R/R PTCL
Won-Seog Kim, MD, PhD, Sungkyunkwan University School of Medicine, Seoul, South Korea, shares the findings from the Phase II REDIRECT study (NCT04101331). This study investigated the treatment of patients with CD30-positive peripheral T-cell lymphoma (CD30+ PTCL) using AFM13, a bispecific anti-CD16A/anti-CD30 antibody which can recruit natural killer (NK) cells to CD30+ tumor cells. Prof. Kim discusses the trial regimen and the overall and complete response rates observed, sharing that NK cell engagement appears to be a promising treatment option for CD30+ PTCL. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
